Whole-Tumor Clearing and Imaging of Intratumor Microbiota in Three Dimensions with miCDaL Strategy.

Adv Sci (Weinh)

State Key Laboratory of Cellular Stress Biology, State-province Joint Engineering Laboratory of Targeted Drugs from Natural Products, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, Fujian, 361102, China.

Published: November 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Acquiring detailed spatial information about intratumor microbiota in situ is challenging, which leaves 3D distributions of microbiota within entire tumors largely unexplored. Here, a modified iDISCO-CUBIC tissue clearing and D-amino acid microbiome labeling-based (miCDaL) strategy are proposed, that integrates microbiota in situ labeling, tissue clearing, and whole-mount tissue imaging to enable 3D visualization of indigenous intratumor microbiota. Leveraging whole-mount spatial resolution and centimeter-scale imaging depth, the 3D biogeography of microbiota is successfully charted across various tumors at different developmental stages, providing quantitative spatial insights in relation to host tumors. By incorporating an immunostaining protocol, 3D imaging of the immunologic microenvironment is achieved in both murine and human mammary tumors that is previously assumed to be bacteria-free. Notably, immune infiltrates, including T cells and NK cells, and tertiary lymphoid structures are conspicuously absent in bacteria-colonized regions. This 3D imaging strategy for mapping Indigenous intratumor microbiota offers valuable insights into host-microbiota interactions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600245PMC
http://dx.doi.org/10.1002/advs.202400694DOI Listing

Publication Analysis

Top Keywords

intratumor microbiota
16
micdal strategy
8
microbiota situ
8
tissue clearing
8
indigenous intratumor
8
microbiota
7
imaging
5
whole-tumor clearing
4
clearing imaging
4
intratumor
4

Similar Publications

Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers.

Signal Transduct Target Ther

September 2025

State Key Laboratory of Molecular Oncology & Department of Medical Oncology & Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Small-cell lung cancer (SCLC), an aggressive neuroendocrine tumor strongly associated with exposure to tobacco carcinogens, is characterized by early dissemination and dismal prognosis with a five-year overall survival of less than 7%. High-frequency gain-of-function mutations in oncogenes are rarely reported, and intratumor heterogeneity (ITH) remains to be determined in SCLC. Here, via multiomics analyses of 314 SCLCs, we found that the ASCL1/MKI67 and ASCL1/CRIP2 clusters accounted for 74.

View Article and Find Full Text PDF

Background: Bladder cancer (BLCA) is a prevalent malignancy with substantial consequences for patient health. This study aimed to elucidate the underlying mechanisms of BLCA through integrated multi-omics analysis.

Methods: Tumor and adjacent tissues from BLCA patients underwent transcriptomic, whole-exome sequencing, metabolomic, and intratumoral microbiome analyses.

View Article and Find Full Text PDF

The discovery of tumor-associated bacteria (TAB) challenges the traditional view of tumors as sterile environments. These microbes are engaged in a complex dialog with the other components of the tumor microenvironment (TME), influencing immunity, metastasis, and treatment response. Yet the precise mechanisms by which TAB influence tumor biology remains incompletely understood.

View Article and Find Full Text PDF

The Microbiome Shaping Cancer Development, Progression, and Therapeutic Response.

Physiol Genomics

September 2025

Department of Bioinformatics, University of Würzburg, Am Hubland, 97074 Würzburg , Germany.

The human microbiome is emerging as a key regulator of cancer biology, modulating tumor development, immune dynamics, and therapeutic responses across diverse malignancies. In this review, recent insights are synthesized regarding how microbial communities (bacterial, fungal, and viral) shape oncogenic signaling, immune checkpoint blockade (ICB) efficacy, and metabolic reprogramming in lung, pancreatic, colorectal, breast, cervical, melanoma, and gastric cancers. Mechanistic links between microbial metabolites, intratumoral colonization, and host immune phenotypes are highlighted proposing that the microbiome constitutes a programmable axis within the tumor immune-metabolic ecosystem.

View Article and Find Full Text PDF

Intratumoral Microbiome-related MRI Model for Predicting Breast Cancer Shrinkage Pattern Following Neoadjuvant Therapy.

Radiology

August 2025

Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan 2nd Rd, Yuexiu District, Guangzhou 510080, China.

Background Patients with breast cancer exhibit different tumor shrinkage patterns (TSPs) after neoadjuvant therapy (NAT), making accurate TSP prediction essential for breast-conserving surgery planning. The intratumoral microbiome influences treatment response, and related imaging features may improve TSP prediction. Purpose To develop an intratumoral microbiome-related MRI model that accurately predicts TSP following NAT.

View Article and Find Full Text PDF